Atreca - Catching It Early

atreca jan10 lt

Shares of biopharmaceutical company Atreca Inc. (BCEL) have gained 13 percent over the last one month as the Company advances its drug candidate into clinical testing.

The Company utilizes a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. One such compound identified using the discovery platform is ATRC-101, which has reacted in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients.

Last month, the FDA cleared the Company's Investigational New Drug (IND) application to initiate a first-in-human phase Ib clinical trial of ATRC-101 in patients with solid tumors. This marked the first IND clearance of a clinical candidate derived from Atreca's differentiated drug discovery platform.

The phase Ib clinical trial of ATRC-101 is expected to be initiated in early 2020.

The Company also anticipates entering into a strategic drug discovery partnership this year.

Founded in 2010, Atreca went public on the Nasdaq Global Select Market on June 20, 2019, offering its shares at a price of $17.00 each.

BCEL has thus far hit a low of $9.51 and a high of $23.65 in the last 1 year. The stock closed Thursday's trading at $16.18, up 13.62%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT